These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26822351)

  • 1. Animal models for addiction medicine: From vulnerable phenotypes to addicted individuals.
    Nader MA
    Prog Brain Res; 2016; 224():3-24. PubMed ID: 26822351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental protocols for behavioral imaging: seeing animal models of drug abuse in a new light.
    Aarons AR; Talan A; Schiffer WK
    Curr Top Behav Neurosci; 2012; 11():93-115. PubMed ID: 22411423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroimaging in drug abuse.
    Lindsey KP; Gatley SJ; Volkow ND
    Curr Psychiatry Rep; 2003 Oct; 5(5):355-61. PubMed ID: 13678555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similarities and Differences in Neuroimaging.
    Sun YK; Sun Y; Lin X; Lu L; Shi J
    Adv Exp Med Biol; 2017; 1010():73-89. PubMed ID: 29098669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonhuman primate models of addiction and PET imaging: dopamine system dysregulation.
    Gould RW; Porrino LJ; Nader MA
    Curr Top Behav Neurosci; 2012; 11():25-44. PubMed ID: 22020537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling human drug abuse and addiction with dedicated small animal positron emission tomography.
    Dalley JW; Fryer TD; Aigbirhio FI; Brichard L; Richards HK; Hong YT; Baron JC; Everitt BJ; Robbins TW
    Neuropharmacology; 2009; 56 Suppl 1():9-17. PubMed ID: 18614184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DSM-5 from the viewpoint of basic study of dependence and addiction.
    Hironaka N
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2016 Oct; 51(5):268-274. PubMed ID: 30462388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET imaging for addiction medicine: From neural mechanisms to clinical considerations.
    Wiers CE; Cabrera E; Skarda E; Volkow ND; Wang GJ
    Prog Brain Res; 2016; 224():175-201. PubMed ID: 26822359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain imaging in nonhuman primates: insights into drug addiction.
    Nader MA; Czoty PW
    ILAR J; 2008; 49(1):89-102. PubMed ID: 18172336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurobiological mechanisms of the reinstatement of drug-conditioned place preference.
    Aguilar MA; Rodríguez-Arias M; Miñarro J
    Brain Res Rev; 2009 Mar; 59(2):253-77. PubMed ID: 18762212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography molecular imaging of dopaminergic system in drug addiction.
    Hou H; Tian M; Zhang H
    Anat Rec (Hoboken); 2012 May; 295(5):722-33. PubMed ID: 22467195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional neuroimaging for addiction medicine: From mechanisms to practical considerations.
    Ekhtiari H; Faghiri A; Oghabian MA; Paulus MP
    Prog Brain Res; 2016; 224():129-53. PubMed ID: 26822357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward biomarkers of the addicted human brain: Using neuroimaging to predict relapse and sustained abstinence in substance use disorder.
    Moeller SJ; Paulus MP
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jan; 80(Pt B):143-154. PubMed ID: 28322982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies.
    Volkow ND; Fowler JS; Wang GJ
    Neuropharmacology; 2004; 47 Suppl 1():3-13. PubMed ID: 15464121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging neurotransmitter release by drugs of abuse.
    Martinez D; Narendran R
    Curr Top Behav Neurosci; 2010; 3():219-45. PubMed ID: 21161755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?
    Hall W; Carter A; Forlini C
    Lancet Psychiatry; 2015 Jan; 2(1):105-10. PubMed ID: 26359616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroimaging for drug addiction and related behaviors.
    Parvaz MA; Alia-Klein N; Woicik PA; Volkow ND; Goldstein RZ
    Rev Neurosci; 2011; 22(6):609-24. PubMed ID: 22117165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse liability of novel 'legal high' designer stimulants: evidence from animal models.
    Watterson LR; Watterson E; Olive MF
    Behav Pharmacol; 2013 Sep; 24(5-6):341-55. PubMed ID: 23839028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET imaging studies in drug abuse.
    Fowler JS; Volkow ND
    J Toxicol Clin Toxicol; 1998; 36(3):163-74. PubMed ID: 9656971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.